FDA Approval Sought for Frontline Tislelizumab in Locally Advanced or Metastatic ESCC
The FDA has accepted for review a biologics license application seeking the approval of tislelizumab for use in the frontline treatment of patients with unresectable, recurrent, locally advanced or metastatic esophageal squamous cell carcinoma.
Source: onclive.com